The MetAP DB was analyzed using six physicochemical properties commonly used in drug design and development to guide the rational optimization of molecules with drug potential. These properties are widely used to describe the drug-like profiling of organic compounds (without metal), however there is a short list of examples that are used as reference, this set of descriptors to systematically study specific metal-based compound scaffolds. Thus, to our knowledge, the results illustrated in Figure are the first systematic study of metal-based drugs that describe their physicochemical properties according to their clinical use. Based on these analyses, metallodrugs exhibit similar physicochemical properties to non-metal approved drugs, which suggests that the conventional descriptors applied to develop non-metal compounds could be used as a benchmark for developing metal-based compounds. Also, these results remark on the importance of considering the category of possible clinical use in the developing process of metalbased compounds. For example, Figure shows that, in general, radiotherapy and radioimagenology drugs exhibit higher variability in their physicochemical descriptors in contrast to other metal-based approved compounds. Properties like molecular weight, TPSA, number of rotatable bonds, and number of H-bond acceptors of compounds approved for photodynamic therapy tend to be higher than those observed in other metal-based approved drugs and non-metal approved drugs. In other words, these results remark that the physicochemical properties benchmarks used during metal-based drug campaigns must consider the potential clinical applications of each kind of compound.